Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | PHGDH | O43175 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
| ▸ | NOS3 | P29474 | 1/20 | 0.40 |
| ▸ | NOS2 | P35228 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17243558 | 0.86 | ALDH1A1 (0.47) | ALDH1A1NPC1GAATHRBATM | |
| SCHEMBL3931362 | 0.86 | GAA (0.45) | ALDH1A1NPC1GAATHRBATM | |
| SCHEMBL16591623 | 0.84 | CYP2D6 (0.45) | ALDH1A1GAATHRBATML3MBTL1 | |
| SCHEMBL14243237 | 0.84 | ALDH1A1 (0.49) | ALDH1A1NPC1GAATHRBATM | |
| SCHEMBL8262867 | 0.84 | ALDH1A1 (0.44) | ALDH1A1NPC1GAATHRBATM | |
| SCHEMBL10089208 | 0.83 | GAA (0.46) | ALDH1A1GAATHRBATML3MBTL1 | |
| SCHEMBL13517101 | 0.81 | GAA (0.41) | ALDH1A1GAATHRBATML3MBTL1 | |
| SCHEMBL1267094 | 0.81 | GAA (0.65) | ALDH1A1NPC1GAATHRBATM | |
| SCHEMBL13328507 | 0.81 | TSHR (0.41) | ALDH1A1NPC1GAATHRBATM | |
| SCHEMBL19368508 | 0.80 | SMN1; SMN2 (0.56) | ALDH1A1NPC1GAAL3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140213541-A1 | AGONISTS OF A2A ADENOSINE RECEPTORS FOR TREATING RECURRENT TUMOR GROWTH | ADENOSINE THERAPEUTICS, LLC (US) | 2014-07-31 | — | — | US | disclosed |
| US-20140213541-A1 | AGONISTS OF A2A ADENOSINE RECEPTORS FOR TREATING RECURRENT TUMOR GROWTH | ADENOSINE THERAPEUTICS, LLC (US) | 2014-07-31 | — | — | US | disclosed |
| US-8551972-B2 | Agonists of A2A adenosine receptors for treating recurrent tumor growth | ADENOSINE THERAPEUTICS, LLC (US) | 2013-10-08 | — | — | US | disclosed |
| US-8551972-B2 | Agonists of A2A adenosine receptors for treating recurrent tumor growth | ADENOSINE THERAPEUTICS, LLC (US) | 2013-10-08 | — | — | US | disclosed |
| US-20130123208-A1 | METHOD OF TREATING MULTIPLE SCLEROSIS WITH ADENOSINE RECEPTOR AGONISTS | The Regents of the University of Colorado, a body corporation (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130123208-A1 | METHOD OF TREATING MULTIPLE SCLEROSIS WITH ADENOSINE RECEPTOR AGONISTS | The Regents of the University of Colorado, a body corporation (US) | 2013-05-16 | — | — | US | disclosed |
| US-8188063-B2 | A2A receptor agonists for the central nervous system; antiinflammatory agents; 2,7-disubstituted-5-amino-pyrazolo[4,3-e]-[1,2,4]-triazolo[1,5-c]pyrimidines, mefloquine, 8-(3-chlorostyryl)caffeine, 3,7,8-trisubstituted-1-propargyl-xanthines; 2,5-disubstituted-7-amino-[1,2,4]triazolo[1,5-a][1,3,5]triazines | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-05-29 | — | — | US | disclosed |
| US-8188063-B2 | A2A receptor agonists for the central nervous system; antiinflammatory agents; 2,7-disubstituted-5-amino-pyrazolo[4,3-e]-[1,2,4]-triazolo[1,5-c]pyrimidines, mefloquine, 8-(3-chlorostyryl)caffeine, 3,7,8-trisubstituted-1-propargyl-xanthines; 2,5-disubstituted-7-amino-[1,2,4]triazolo[1,5-a][1,3,5]triazines | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-05-29 | — | — | US | disclosed |
| US-8178509-B2 | Method to treat sickle cell disease | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178509-B2 | Method to treat sickle cell disease | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-05-15 | — | — | US | disclosed |
| WO-2008124150-A1 | METHOD OF TREATING ENTERITIS, INTESTINAL DAMAGE, AND DIARRHEA FROM C. DIFFICILE WITH AN A2A ADENOSINE RECEPTOR AGONIST | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2008-10-16 | — | — | WO | disclosed |
| US-20080064653-A1 | USE OF ADENOSINE A2A MODULATORS TO TREAT SPINAL CORD INJURY | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2008-03-13 | — | — | US | disclosed |
| US-20080064653-A1 | USE OF ADENOSINE A2A MODULATORS TO TREAT SPINAL CORD INJURY | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2008-03-13 | — | — | US | disclosed |
| US-20080027022-A1 | METHOD TO TREAT GASTRIC LESIONS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2008-01-31 | — | — | US | disclosed |
| US-20080027022-A1 | METHOD TO TREAT GASTRIC LESIONS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2008-01-31 | — | — | US | disclosed |
| US-20080009460-A1 | METHOD TO TREAT SICKLE CELL DISEASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-01-10 | — | — | US | disclosed |
| US-20080009460-A1 | METHOD TO TREAT SICKLE CELL DISEASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-01-10 | — | — | US | disclosed |
| WO-2007120972-A2 | METHOD TO TREAT SICKLE CELL DISEASE | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007092936-A9 | METHOD TO TREAT GASTRIC LESIONS | UNIV VIRGINIA (US) | 2007-10-18 | — | — | WO | disclosed |
| WO-2007092936-A2 | METHOD TO TREAT GASTRIC LESIONS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123208-A1 | METHOD OF TREATING MULTIPLE SCLEROSIS WITH ADENOSINE RECEPTOR AGONISTS | ADORA3, ADORA2A, ADORA2B | ALDH1A1 2031/4885NPC1 3585/4885GAA 3648/4885 |
| US-20080064653-A1 | USE OF ADENOSINE A2A MODULATORS TO TREAT SPINAL CORD INJURY | ADORA2A, ADORA2B, ADORA3 | ALDH1A1 325/4885NPC1 4003/4885GAA 4289/4885 |
| US-20140213541-A1 | AGONISTS OF A2A ADENOSINE RECEPTORS FOR TREATING RECURRENT TUMOR GROWTH | ADORA2A, ADORA3, ADORA1 | ALDH1A1 659/4885NPC1 3682/4885GAA 4509/4885 |
| US-20080009460-A1 | METHOD TO TREAT SICKLE CELL DISEASE | PDE4A, ADORA2A, PDE4B | ALDH1A1 310/4885NPC1 4505/4885GAA 588/4885 |
| US-20080027022-A1 | METHOD TO TREAT GASTRIC LESIONS | ADORA2A, ADORA2B, PDE4A | ALDH1A1 149/4885NPC1 4829/4885GAA 877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.